PD-L1 expression on melanoma cells has shown to enrich for responders to treatment with anti-PD-1 antibodies however in all studies evaluating anti-PD-1 therapies, a significant proportion of PD-L1 negative patients benefitted from treatment (32–34). The gene discussed is CD274; the disease is melanoma.